Anisomycin suppresses Jurkat T cell growth by the cell cycle-regulating proteins

Pharmacol Rep. 2013;65(2):435-44. doi: 10.1016/s1734-1140(13)71019-3.

Abstract

Background: Recent studies have shown that anisomycin significantly inhibits mammalian cell proliferation, but its mechanism remains unclear. In this study, Jurkat T cells were used to first explore a relationship between effect of anisomycin on them and alteration of cell cycle-regulating proteins.

Methods: Cell colony formation, CCK-8 assay, flow cytometry, RT-PCR and western blot were employed to evaluate correlation of ten cell cycle-regulating proteins with suppression of the cell proliferation and arrest of the cell cycle by anisomycin.

Results: Our data showed that anisomycin inhibited the colony-formation and proliferation of Jurkat T cells in a dose-dependent manner, and arrested the cells into S and G2/M phases with the production of sub-diploid cells. The levels of P21, P-P27 and P53/P-P53 reached their peaks 4 h after anisomycin treatment, presenting a positive correlation with anisomycin concentration, and P16, P-P21, P27, P57, P73/P-P73 and P-Rb changed little with the prolonged exposure time or increased concentrations of anisomycin. But the level of Rb protein was increased at 24 h after the treatment of anisomycin. The expression of an inverted CCAAT box binding protein (ICBP90) in Jurkat T cells came to decrease 12 h after the treatment of anisomycin, presenting a negative correlation with anisomycin concentration. Subsequently, the expression of P-CDK2 was also decreased at 24 h, presenting an obviously negative correlation, whereas P-CDK1 showed no differences among the differently treated Jurkat T cells. Furthermore, the level of P21 and P53 mRNA was increased with the enhanced concentrations of anisomycin.

Conclusion: The results indicate that anisomycin may activate the P53/P21/P27 signaling to decrease the expression of ICBP90, inhibit expression of P-CDK2 to block the cells into S and G2/M phases, and finally result in proliferation inhibition of Jurkat T cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anisomycin / administration & dosage
  • Anisomycin / pharmacology*
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology*
  • Blotting, Western
  • CCAAT-Enhancer-Binding Proteins / genetics
  • CDC2 Protein Kinase / metabolism
  • Cell Cycle Checkpoints / drug effects*
  • Cell Proliferation / drug effects*
  • Cyclin-Dependent Kinase 2 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism
  • Dose-Response Relationship, Drug
  • Flow Cytometry
  • Humans
  • Jurkat Cells
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects
  • Time Factors
  • Tumor Suppressor Protein p53 / metabolism
  • Ubiquitin-Protein Ligases

Substances

  • Anti-Bacterial Agents
  • CCAAT-Enhancer-Binding Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • Tumor Suppressor Protein p53
  • Cyclin-Dependent Kinase Inhibitor p27
  • Anisomycin
  • UHRF1 protein, human
  • Ubiquitin-Protein Ligases
  • CDC2 Protein Kinase
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2